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Abstract
Studies have suggested that the nuclear receptor corepressor 1 (NCOR1) could play an important role in human cancers.
However, the detailed molecular mechanisms by which it functions in vivo to affect cancer progression are not clear. The
present study elucidated the in vivo actions of NCOR1 in carcinogenesis using a mouse model (ThrbPV/PV mice) that
spontaneously develops thyroid cancer. ThrbPV/PV mice harbor a dominantly negative thyroid hormone receptor b (TRb)
mutant (denoted as PV). We adopted the loss-of-the function approach by crossing ThrbPV mice with mice that globally
express an NCOR1 mutant protein (NCOR1DID) in which the receptor interaction domains have been modified so that it
cannot interact with the TRb, or PV, in mice. Remarkably, expression of NCOR1DID protein reduced thyroid tumor growth,
markedly delayed tumor progression, and prolonged survival of ThrbPV/PVNcor1DID/DID mice. Tumor cell proliferation was
inhibited by increased expression of cyclin-dependent kinase inhibitor 1 (p21waf1/cip1; Cdkn1A), and apoptosis was activated
by elevated expression of pro-apoptotic BCL-Associated X (Bax). Further analyses showed that p53 was recruited to the p53-
binding site on the proximal promoter of the Cdkn1A and the Bax gene as a co-repressor complex with PV/NCOR1/histone
deacetylas-3 (HDAC-3), leading to repression of the Cdkn1A as well as the Bax gene in thyroids of ThrbPV/PV mice. In thyroids
of ThrbPV/PVNcor1DID/DID mice, the p53/PV complex could not recruit NCOR1DID and HDAC-3, leading to de-repression of
both genes to inhibit cancer progression. The present studies provided direct evidence in vivo that NCOR1 could function as
an oncogene via transcription regulation in a mouse model of thyroid cancer.
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Introduction
Thyroid hormone receptors (TRs) are critical in mediating the
genomic actions of the thyroid hormone (T3) in growth,
development, differentiation, and maintaining metabolic homeo-
stasis. Two TR genes, a and b, located on two different
chromosomes, encode three major T3 binding TR isoforms (a1,
b1, and b2). Studies using genetically engineered mice showed
that, in vivo, TR isoforms have common functions, but can also
exert isoform-dependent actions in target tissues [1,2]. The
transcription activity of TR is regulated at multiple levels. In
addition to the regulation by T3 and types of DNA binding
elements in the promoters of target genes, the transcriptional
activity of TR is fine-tuned by a host of nuclear coactivators and
corepressors [3,4]. In the absence of T3, the unliganded TR
recruits the nuclear receptor corepressor 1 (NCOR1) and the
nuclear receptor corepressor 2/silencing mediator for retinoid and
thyroid hormone receptors (NCOR2/SMRT) for transcriptional
repression. Binding of T3 leads to a conformational change in the
TR that releases the NCOR1/NCOR2 complex and allows for
the recruitment of a multiprotein coactivator complex for
transcriptional activation [5].
The important regulatory role of NCOR1 in receptor actions is
evident in its aberrant interaction with receptors underlying
human diseases such as resistance to thyroid hormone (RTH) [6,7]
and lipodystrophic severe insulin resistance [8]. RTH is caused by
mutations in the THRB gene [9,10]. Mutations of the peroxisome
proliferator-activated receptor c (PPARc) lead to lipodystrophic
severe insulin resistance [8]. In addition, aberrant interaction of
NCOR1/SMRT with the fused gene products of the retinoic acid
receptor a gene (RARa) or with the promyelocytic leukemia gene
(PML) (PML-RAR-a) or with the promyelocytic leukemia zinc
finger gene (PLZF) (PLZF-RAR-a) results in blocking myeloid
differentiation [11]. The involvement of NCOR1 in other human
cancers such as breast and bladder cancers was demonstrated by a
close association of NCOR1 abnormal expression with cancer
development [12,13,14,15]. Recent studies by The Cancer
Genome Atlas (TCGA) Research Network also uncovered
homozygous gene deletion of NCOR1 in some patients with
colon and rectum adenocarcinoma [16], prostate adenocarcinoma
[17], ovarian carcinoma [18] or liver hepatocellular carcinoma
(unpublished-Provisional in TCGA data base). Moreover, non-
sense mutations and splicing variants of NCOR1 were also found in
patients with breast cancer [19]. While these association studies
raised the possibility that NCOR1 could act to affect cancer
progression, direct evidence of its roles in carcinogenesis in vivo is
still lacking.
The availability of a mouse model that spontaneously develops
metastatic follicular thyroid cancer (FTC) provided us with a
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powerful tool to assess the role of NCOR1 in cancer development
and progression. The ThrbPV/PV mouse harbors a knockin
dominant negative mutation, known as PV, in the Thrb gene
locus [20]. The PV mutation was identified in a patient suffering
from resistance to thyroid hormone [21]. As ThrbPV/PV mice age,
their thyroids undergo pathological changes from hyperplasia to
capsular and vascular invasion, anaplasia, and eventual metastasis
to the lung [22]. The pathological progression, route, and
frequency of metastasis in ThrbPV/PV mice are similar to that in
human FTC. Extensive molecular analyses of altered signaling
pathways show that, as found in human FTC, ThrbPV/PV mice
exhibit aberrant signaling pathways that include constitutive
activation of phosphatidyl inositol 3-kinase (PI3K)/Akt [23,24]
and integrin–Src–MAPK signaling [25] and aberrant accumula-
tion of the oncogenic pituitary tumor transforming gene protein
(PTTG) [26,27] and ß-catenin [28]. Thus, the ThrbPV/PV mouse
model faithfully recapitulates the molecular aberrations found in
human thyroid cancer and is indeed a preclinical mouse model of
FTC.
In the present studies, we adopted the loss-of-the function
approach by crossing ThrbPV with mice that globally express an
NCOR1 mutant protein (NCOR1DID). In this NCOR1DID
mutant protein, two most amino terminal receptor interaction
domains termed RID 3 and RID2, are missing. This mutant
cannot associate with TR, as RID3 is absolutely required for
NCOR1-TR interaction [29,30,31]. Consistently, we also showed
that NCOR1DID mutant protein cannot interact with TRbPV
in vivo [32]. The lack of interaction of TRbPV with NCOR1DID
results in the amelioration of symptoms of resistance to thyroid
hormone in ThrbPVNcor1DID/DID mice, indicative that NCOR1
regulates the dominant negative action of TRb mutants in vivo
[32].
The present studies show that the expression of NCOR1DID in
the thyroid of ThrbPV/PV mice inhibited tumor growth, prolonged
survival, and delayed cancer progression. Tumor cell proliferation
was inhibited by the increased expression of cyclin-dependent
kinase inhibitor 1 (p21/WAF1; Cdkn1A), and the apoptosis was
induced by the activated expression of the Bcl-2–associated X
protein (BAX). Both the Cdkn1A and the BAX genes are direct
downstream target genes of the tumor suppressor, p53. Detailed
molecular analyses showed that the lack of receptor interaction
domain in NCOR1DID led to an inability of the p53/PV complex
to recruit the NCOR1/histone deacetylase-3 repressor complex to
the promoters of these target genes, resulting in increased
repression of these genes to inhibit cancer progression. The
present study provided direct evidence in vivo to demonstrate that
the NCOR1 could function as an oncogene via transcription
regulation in thyroid carcinogenesis in a mouse model.
Materials and Methods
Mouse Strains
The animal study was carried out according to the protocol
approved by the National Cancer Institute Animal Care and Use
Committee. Mice harboring the ThrbPV gene (ThrbPV mice) were
prepared and genotyped as described earlier [20]. ThrbPV/
PVNcor1DID/DID mice were bred by first crossing Thrb+/+Ncor1DID/
+ mice [29] with ThrbPV/+ mice and then by crossing ThrbPV/
+Ncor1DID/DID mice with ThrbPV/+Ncor1DID/DID mice [32]. Mice
with different genotypes used in the present study were
intercrossed several generations, and littermates with a similar
genetic background were used in all experiments. Mice were
monitored until they became moribund and therefore euthanized.
Thyroids and other tissues were collected from ThrbPV/PVNcor1+/+
mice and ThrbPVPVNcor1DID/DID mice for weighing, histological
analysis, and molecular and biochemical studies.
RNA Isolation and Quantitative Real-Time RT-PCR
Total RNA was extracted from thyroids of mice using TRIzol
(Invitrogen) according to the manufacturer’s instructions. Quan-
titative real-time RT-PCR was performed with a Quantitect
SYBR Green RT-PCR kit (QIAGEN, Valencia, CA), according to
the manufacturer’s instructions and using a LightCycler thermal
cycler (Roche Diagnostics). Total RNA (200 ng) was used in RT-
PCR determinations as described previously [33]. The specific
primers were as follows: mp21 forward, 59-CGCCGCGGTGTCA-
GAGTC-39 and reverse, 59-GCAGCAGGGCAGAGGAAG-39;
mBax forward, ’-CCACCAGCTCTGAACAGATC-39 and re-
verse, 59-CAGCTTCTTGGTGGACGCAT-39; mp53 forward,
59-AGAGACCGCCGTACAGAAGA-39 and reverse, 59-
CTGTAGCATGGGCATCCTTT-39.
Western Blot Analysis and Co-immunoprecipitation
Nuclear extracts of thyroids were prepared as previously
described [32]. The protein samples (25 mg) were analyzed by
Western blot as described previously [28]. Anti-phosphorylated
retinoblastoma protein (pRb) (Ser780, #9307) and PUMA
(#7467) were from Cell Signaling Technologies (Beverly, MA)
(1:500 dilution), anti-cyclin D1 (sc-450), BAX (sc-7480), Rb (sc-50),
p21 (sc-6246) and p27 (sc-1641) antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA) and used at a 1:200
dilution. Anti-p53 antibodies (OP03) were from Calbiochem
(1:500 dilution). Band intensities were quantified by using NIH
IMAGE software (ImageJ 1.34 s; Wayne Rasband, NIH).
For co-immunoprecipitation to show the physical interaction of
p53 with PV, 0.5 mg of total thyroid extracts was first incubated
overnight with rabbit anti-TR (Code 600-401-A96, Rockland) in
Tris-buffered saline-0.6% NP-40 with protease inhibitors (Roche)
at 4uC. The samples were then mixed with 20 ml protein A-
agarose (Roche) at 4uC for 2 hours, and beads were washed five
times with TBS-0.6% NP-40 containing protease inhibitors.
Bound proteins were analyzed by Western blot analysis using
antibodies for p53 (OP03; Millipore, Inc.,) at a 1:500 dilution and
anti-NCOR1 (PHQQ; 2 mg/mL) [32].
Histological Analysis
Thyroid gland, lung, and heart were dissected, fixed in 10%
neutral buffered formalin (Sigma-Aldrich, St. Louis, MO), and
subsequently embedded in paraffin. Sections of 5-mm thickness
were prepared and stained with hematoxylin and eosin (H&E). For
each animal, single random sections through the thyroid, through
the lung, and through the heart were examined.
Immunohistochemistry
IHC was performed as previously described with some
modification [25]. Formalin-fixed paraffin thyroid sections were
deparaffinized, rehydrated, heated to 98uC in 0.05% citraconic
anhydride, pH 7.4 (Sigma-Aldrich, St. Louis, MO), for 1 hour and
then blocked for 1 hour in 2% normal goat serum at room
temperature. After washing in phosphate-buffered saline, slides
were incubated at 4uC overnight with Ki-67 primary antibody
(1:300 dilution; Thermo Scientific, Fremont, CA; #RB-9043-P0).
After washing, slides were incubated with goat anti-rabbit
secondary antibody for 1 hour at room temperature and rinsed
in phosphate-buffered saline. Slides were then incubated in 3,39-
diaminobenzidene (DAB substrate kit for peroxidase; Vector
Laboratories, Burlingame, CA; SK-4100), and after staining
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development, they were counterstained in Gill’s Hematoxylin,
rinsed and mounted in Permount (Fisher Scientific, Pittsburgh,
PA). The proliferative index was calculated as the percentage of
Ki-67-positive nuclei to the total number of nuclei on the thyroid
section. Counting was performed using National Institutes of
Health (NIH) IMAGE software (ImageJ 1.34 s; Wayne Rasband,
NIH, Bethesda, MD).
Chromatin Immunoprecipitation (ChIP) Assay
The ChIP assay was carried out using chromatin DNA
prepared from thyroid tumors (50 mg/assay) of Thrb1PV/
PVNcor1+/+ mice and Thrb1PV/PVNcor1 DID/DID mice, as described
previously [34]. The immunoprecipitated-DNA in 50 ml of TE
and quantitative PCR was performed with 7900HT Fast Real-
Time PCR System (Applied Biosystems) using QuantiFast SYBR
Green RT-PCR Kit (204154, QIAGEN). The enrichment in
signals was calculated as immunoprecipitation signals versus whole
cell lysate inputs. The fold changes of thyroid tumors of Thrb1PV/
PVNcor1+/+ or Thrb1PV/PVNcor1DID/DID ChIP were normalized by
negative control (mouse IgG). The ChIP primers used were
Cdkn1A forward, 59- TTTCTATCAGCCCCAGAGGA-39; and
reverse, 59- TCACCCCACAGCTGGTAGTT-39 and Bax for-
ward, 59- GGGGCGCGCGGATCCATTCC-39; and reverse, 59-
GCTTCTGATGGACAGGGGGC-39.
Statistical Analysis
All data are expressed as mean 6 the SEM. Differences
between groups were examined for statistical significance using
Student’s t test with the use of GraphPad Prism 4.0a (GraphPad
Software); p,0.05 is considered statistically significant.
Results
NCOR1DID Prolongs Survival and Delays Thyroid
Carcinogenesis of ThrbPV/PV Mice
We have previously shown that ThrbPV/PV mice have high
mortality caused by FTC [22]. We monitored the effects of the
expression of NCOR1DID on thyroid carcinogenesis by first
comparing the survival of ThrbPV/PVNcor1DID/DID mice with that of
ThrbPV/PVNcor1+/+ mice. Mice were monitored until they became
moribund with signs of palpable tumors, rapid weight loss,
hunched postures, and labored breathing. Figure 1A shows that
ThrbPV/PVNcor1DID/DID mice survived significantly longer (p,0.01;
50% survival age: 11.3 months, n = 29) than did ThrbPV/PVNcor1+/+
mice (50% survival age: 9.3 months, n = 58) during the 15-month
observation period. Figure 1B shows that the expression of
NCOR1DID led to a significant 35% reduction in thyroid weight
in ThrbPV/PVNcor1DID/DID mice (data set 2 vs. 1; p,0.0001).
The effect of NCOR1DID on the pathological progression was
assessed by histopathological analysis as the ThrbPV/PVNcor1DID/DID
mice aged. Figure 2A shows representative pathological features of
the thyroids and lungs from the 3- to 15-month-old ThrbPV/
PVNcor1+/+ and ThrbPV/PVNcor1DID/DID mice (left and right
columns, respectively). In the thyroids of ThrbPV/PVNcor1+/+ mice
at the age of 7 months, advanced vascular invasion and focal
anaplasia were frequently observed (arrows in Figure 2Aa and
2Ac, respectively). Moreover, lung metastases (Figure 2Ae, arrows)
were frequent in ThrbPV/PVNcor1+/+ mice. In ThrbPV/PVNcor1DID/
DID mice, however, vascular invasion was rarely observed
(Figure 2Ab), but with no detectable anaplasia (Figure 2Ad) and
a marked reduction in the occurrence of lung metastasis
(Figure 2Af). These pathohistological observations are summarized
in Figure 2B. At the younger age of 3–5 months, a lower
occurrence of capsular invasion (,20%) was observed for ThrbPV/
PVNcor1DID/DID mice than for ThrbPV/PVNcor1+/+ mice (Figure 2Ba),
but a similar occurrence frequency of capsular invasion was
detected for both mutant mice at older age (.7 months of age). No
vascular invasion, anaplasia, or lung metastases were found in
ThrbPV/PVNcor1DID/DID mice (Figure 2Bb, c, and d) at younger ages
of 3–5 months. For mice older than 7 months, the occurrence
frequency of vascular invasion, anaplasia, and lung metastasis were
80%, 15%, and 60%, respectively, for ThrbPV/PVNcor1+/+ mice
(Figure 2Bb, c, and d). However, the occurrence of vascular
invasion and lung metastasis were 14% and 10%, respectively, for
ThrbPV/PVNcor1DID/DID mice, with no occurrence of anaplasia.
Taken together, these results indicate that the expression of
NCOR1DID delayed thyroid cancer progression and blocked loss
of differentiation (anaplasia) in ThrbPV/PV mice.
NCOR1DID Reduces Thyroid Growth by Inhibiting Cell
Proliferation in ThrbPV/PVNcor1DID/DID Mice
The fact that thyroid growth was reduced in ThrbPV/PVNcor1DID/
DID mice (Figure 1B) prompted us to ask whether thyroid tumor
cell proliferation was inhibited. We therefore examined the protein
abundance of the nuclear proliferation marker, Ki-67, by
immunohistochemical analysis. Figure 3A.I-a and -b show
representative examples of intensive nuclear staining in thyroids
of two ThrbPV/PVNcor1+/+ mice. In contrast, fewer nuclei were
immuno-stained with Ki-67 proliferation marker in thyroids of
ThrbPV/PVNcor1DID/DID mice (Figure 3A.I-c and -d, n = 2). Cells
with Ki-67 immuno-stained nuclei were counted and the
quantitative data are shown in Figure 3A.II. The quantitative
analysis shows that the number of thyroid cells with Ki-67 stained
nuclei was 50% lower in ThrbPV/PVNcor1DID/DID mice than in
ThrbPV/PVNcor1+/+ mice, indicating decreased cell proliferation in
the thyroid of ThrbPV/PVNcor1DID/DID mice.
This finding was further supported by the biochemical analysis
in which the protein abundance of a key cell cycle regulator, cyclin
D1, was markedly lower in the thyroids of ThrbPV/PVNcor1DID/DID
mice (Figure 3B.I, panel a, lanes 3 & 4) than in ThrbPV/PVNcor1+/+
mice (lanes 1 & 2). Moreover, the reduced cyclin D1 led to a lower
protein abundance of phosphorylated retinoblastoma protein
(pRb) (Figure 3B.I, panel b, compare lanes 1 & 2 with lanes 3 &
4) without changing the total Rb protein levels (panel c). The
reduction in the phosphorylated Rb impeded the progression of
the cell cycle from the G1 to the S phase. Consistently, the protein
abundance of cyclin-dependent kinase inhibitor p21 and p27
(Figure 3B.I, panels d and e, respectively) was also lower in the
thyroids of ThrbPV/PVNcor1DID/DID mice than in ThrbPV/PVNcor1+/+
mice (compare lanes 3–4 to lanes 1–2). The quantitative data of
the band intensities are shown in Figure 3B.II. Collectively, these
results indicate that the expression of the NCOR1DID led to
inhibition of tumor cell proliferation, in part, by delaying the G1-S
cell cycle progression.
Whether apoptosis also contributed to decreased thyroid tumor
growth shown in Figure 1B was also evaluated by examining the
key regulators of apoptosis. The protein abundance of Bcl-2–
associated X protein (BAX), which promotes apoptosis, was higher
in thyroids of ThrbPV/PVNcor1DID/DID mice than in ThrbPV/
PVNcor1+/+ mice (Figure 4Aa, compare lanes 3 & 4 with 1 & 2).
PUMA, which is a BH3 (Bcl-2 homology domain 3)-only protein
that induces apoptosis through the mitochondria pathway, was
also higher in thyroids of ThrbPV/PVNcor1DID/DID mice than in
ThrbPV/PVNcor1+/+ mice (Figure 4Ab, compare lanes 3 & 4 with 1 &
2). The quantitative band intensities are shown in Figure 4Ba,
indicating a 2-fold increase in BAX and PUMA protein level.
Furthermore, the increased cleaved caspase 3 (Figure 4A, panel b,
lanes 3 & 4) and the decreased total poly ADP-ribose polymerase
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(PARP) but increased cleaved PARP (panel c, upper band and
lower band, respectively, in lanes 3 & 4) in ThrbPV/PVNcor1DID/DID
mice as compared with ThrbPV/PVNcor1+/+ mice were indicative of
the elevated apoptotic activity in thyroid tumor cells of ThrbPV/
PVNcor1DID/DID mice (also see quantitative data in Figure 4Bb).
These results indicate that in addition to delaying the G1-S cell
cycle progression, the increased apoptotic activity in thyroids of
ThrbPV/PVNcor1DID/DID mice also contributed to lower thyroid
growth.
Figure 1. Expression of NCOR1DID increases survival of ThrbPV/PVNcor1DID/DID mice. (A) Kaplan-Meier survival curves for ThrbPV/PVNcor1+/+
and ThrbPV/PVNcor1DID/DID mice up 15 months of age. ThrbPV/PVNcor1DID/DID (n = 29) survived significantly longer than ThrbPV/PVNcor1+/+ mice (n = 58)
(p,0.0001). (B) Thyroids of ThrbPV/PVNcor1+/+ and ThrbPV/PVNcor1DID/DID mice at the ages of 5–15 months were dissected and weighed. The data are
presented as the ratios of thyroid weight to body weight. The differences between the thyroid weights of ThrbPV/PVNcor1+/+ and ThrbPV/PVNcor1DID/DID
mice were significant (p,0.0001), as determined by Student’s t-test analysis.
doi:10.1371/journal.pone.0067954.g001
Figure 2. Expression of NCOR1DID delays thyroid cancer progression in ThrbPV/PVNcor1DID/DID mice. (A) Hematoxylin and eosin (H&E)
staining of thyroid sections (top and middle rows) and lung sections (bottom row) of ThrbPV/PVNcor1+/+ (a, c, and e) and ThrbPV/PVNcor1DID/DID (b, d, and
f) mice. Histological sections from tissues of ThrbPV/PVNcor1+/+ mice showed evidence of (a) vascular invasion in thyroid (arrow), (c) anaplasia in thyroid
(arrows), and (e) metastatic lesions in lung (arrows). Sections of thyroids and lungs from ThrbPV/PVNcor1DID/DID showed blood vessels (b) without
vascular invasion (arrow), (d) without anaplasia, and (f) lung without metastatic lesions. (B) Comparison of age-dependent percentage occurrence of
capsular invasion (a), vascular invasion (b), anaplasia (c), and lung metastasis (d). The data are expressed as the percentage of occurrence of total
mutant mice examined. The symbol ‘‘#’’ indicates 0% occurrence.
doi:10.1371/journal.pone.0067954.g002
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Inhibition of Tumor Growth by Activation of the p53-
signaling Pathway in the Thyroids of ThrbPV/PVNcor1DID/
DID Mice
The findings that protein abundances of p21 and BAX were
altered as shown above prompted us to examine whether their
expression at the mRNA level was also affected. Indeed, we found
that Cdkn1A (p21WAF1) mRNA levels were significantly higher in
the thyroid of ThrbPV/PVNcor1DID/DID mice than in ThrbPV/
PVNcor1+/+ mice (Figure 5A, bar 2 vs. bar 1). Similarly, Bax
mRNA level was higher in the thyroid of ThrbPV/PVNcor1DID/DID
mice than in ThrbPV/PVNcor1+/+ mice (Figure 5B, bar 4 vs. bar 3).
These two genes are directly regulated by p53 [35,36]. We
therefore hypothesized that altering the activity of p53 in thyroids
of ThrbPV/PVNcor1DID/DID mice would lead to activation of
transcription of the Cdkn1A and Bax genes. We first examined
whether the expression of p53 mRNA and protein was altered,
thereby changing the activity in the thyroid of ThrbPV/PVNcor1DID/
DID mice. We found that the expression of NCOR1DID had no
effects of the expression of p53 at the mRNA level (bars 5 and 6,
Figure 5A). In addition, we found that the protein abundance of
p53 was similarly low in the thyroid of ThrbPV/PVNcor1+/+ and
ThrbPV/PVNcor1DID/DID mice (Figure 5B, upper panel, lanes 3 and
4, respectively). Therefore, the higher Cdkn1A and Bax mRNA
Figure 3. Expression of NCOR1DID inhibits proliferation of thyroid tumor cells of ThrbPV/PVNcor1DID/DID mice. (A.I) Two representative
microphotographs of stained Ki-67 on thyroid sections of ThrbPV/PVNcor1+/+ (a and b represent two different mice) and ThrbPV/PVNcor1DID/DID mice (c
and d represent two different mice). In the thyroids of ThrbPV/PVNcor1DID/DID mice, fewer thyroid cells were stained with Ki-67 than in thyroids of
ThrbPV/PVNcor1+/+ mice (arrows). (A.II) Positively nuclear Ki-67-stained thyroid cells from ThrbPV/PVNcor1DID/DID and ThrbPV/PVNcor1+/+ mice were
counted and expressed as percentage of total cells. The percentage of proliferating cells was significantly lower in the thyroids of ThrbPV/PVNcor1DID/
DID than ThrbPV/PVNcor1+/+ mice. (B.I) Nuclear protein extracts were prepared from thyroid tumors of ThrbPV/PVNcor1+/+ (lanes 1 and 2) or ThrbPV/
PVNcor1DID/DID (lanes 3 and 4) mice. Western blot analysis of cyclin D1, phosphorylated Rb, total Rb, p21, and p27 are as marked, and actin (panel f)
was used as loading control. (B.II) Quantitation of band intensities shown in (B.I). The protein abundances of cyclin D1 and phosphorylated Rb were
lower in the thyroids of ThrbPV/PVNcor1DID/DID mice, whereas the protein abundance of p21 and p27 were higher in the thyroids of ThrbPV/PVNcor1DID/
DID mice.
doi:10.1371/journal.pone.0067954.g003
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levels were not due to activation of p53 transcription activity by
the elevated p53 protein expression. Because it has been previously
shown that wild-type TRs physically interact with p53 and
negatively regulate the transcriptional activity of p53 [37,38], we
next explored the possibility that the activity of p53 could be
altered via interaction with PV in thyroids of mutant mice. Co-
immunoprecipitation analysis showed that PV was associated with
p53 in the thyroid of ThrbPV/PVNcor1+/+ mice (Figure 5B, upper
panel, lane 1). PV was also similarly associated with p53 in the
thyroid of ThrbPV/PVNcor1DID/DID mice (Figure 5B, upper panel,
lane 2). Importantly, co-immunoprecipitation further showed that
PV was also associated with NCOR1 in the thyroid nuclear
extracts of ThrbPV/PVNcor1+/+ mice (Figure 5B, lower panel, lane 1),
but did not interact with NCOR1DID in the thyroid nuclear
extracts of ThrbPV/PVNcor1DID/DID mice (lane 2). Lanes 3 and 4
show that a similar amount of NCOR1 and NCOR1DID,
respectively, was detected by direct Western blot analysis
(Figure 5B, lower panel). These data indicate that PV interacted
with p53 and NCOR1 in a ternary complex (p53/PV/NCOR1) in
the thyroid of ThrbPV/PVNcor1+/+ mice, but formed only a p53/PV
complex in the thyroid of ThrbPV/PVNcor1DID/DID mice.
The findings that Cdkn1A and Bax mRNA were higher in the
thyroid of ThrbPV/PVNcor1DID/DID than ThrbPV/PVNcor1+/+ mice
(Figure 5A) provided us with a tool to further investigate the
mechanisms by which NCOR1 regulated thyroid carcinogenesis.
We therefore used a chromatin immunoprecipitation (ChIP) assay
to understand how the transcriptional activity of p53 was activated
in the thyroid of ThrbPV/PVNcor1DID/DID mice to drive the
expression of the Cdkn1A and Bax genes to inhibit tumor growth.
Figure 5C shows that when anti-p53 antibodies were used in the
ChIP assays, a strong signal above the background (bar 2 vs. bar 1)
was detected to indicate that p53 was recruited to the p53 binding
sites on the promoter region of the Cdkn1A gene (–1961 to –
1942 bp; see Figure 6A) [35] in the thyroid of ThrbPV/PVNcor1+/+
mice (Figure 5C, bar 2). Importantly, when anti-PV antibodies
were used in the ChIP, significant recruitment of PV to the
promoter of the Cdkn1A gene was detected (Figure 5C, bar 3).
Concurrently, using anti-NCOR1 and histone deacetylase-3
(HDAC-3) antibodies, we also found that NCOR1 and HDAC-3
were recruited to the p53/PV complexes (Figure 5C, bars 4 and 5,
respectively). These results indicate that in thyroid tumors of
ThrbPV/PVNcor1+/+ mice, the p53/PV/NCOR1/HDAC-3 repres-
sor complex was recruited to the promoter of the Cdkn1A gene to
repress the expression of the Cdkn1A gene. In contrast, in thyroids
of ThrbPV/PVNcor1DID/DID mice (Figure 5C), although p53 (bar 7)
and PV (bar 8) were recruited to the p53 binding sites on the
promoter of the Cdkn1A gene, no recruitment of NCOR1DID or
HDAC-3 was found with the p53/PV complexes (Figure 5C, bars
9 and 10, respectively; see also Figure 6B). Similar ChIP analysis
shows the significant recruitment of p53/PV/NCOR1/HDAC-3
to the p53 binding sites (nt -781 to -768) on the promoter of the
Bax gene in the thyroids of ThrbPV/PVNcor1+/+ mice (Figure 5D;
bars 2–5). But in the thyroids of ThrbPV/PVNcor1DID/DID mice, only
significant recruitment of p53/PV to the p53 binding sites on the
Bax promoter was detected (Figure 5D, bars 7 and 8), but no
recruitment of NCOR1DID or HDAC-3 to the promoter of the
Bax promoter was observed (bars 9 and 10 vs. bar 6). These in vivo
results indicate that in thyroids of ThrbPV/PVNcor1DID/DID mice, the
lack of interaction of PV with NCOR1DID reversed the repressive
effect of NCOR1/HDAC-3. This, in turn, re-activated the p53
transcription activity to increase the expression of the Cdkn1A and
Bax genes, thus delaying tumor progression by inhibiting tumor
cell proliferation and activation of apoptosis.
Discussion
Using a preclinical mouse model of thyroid cancer, we showed
that the expression of NCOR1DID in the thyroid of ThrbPV/PV
mice decreased tumor growth, delayed cancer progression, and
increased survival. Analyses of key regulators underlying these
reduced cancer phenotypes identified the increased expression of
two p53 downstream direct target genes, the Cdkn1A and Bax
genes. We further showed that p53 was associated with PV on the
p53 binding sites of the promoters of the Cdkn1A and the Bax
genes. However, NCOR1DID, lacking the receptor interaction
domain, cannot be recruited by p53/PV to form the NCOR1-
DID/HDAC-3 associated repressor complex, leading to the
Figure 4. Expression of NCOR1DID promotes apoptosis of thyroid tumor cells of ThrbPV/PVNcor1DID/DID mice. (A) Nuclear protein extracts
were prepared from thyroid tumors of ThrbPV/PVNcor1+/+ (lanes 1 and 2) or ThrbPV/PVNcor1DID/DID (lanes 3 and 4) mice. Shown are Western blot analyses
of BAX (panel a), PUMA (panel b), cleaved caspase 3 (panel c), PARP and cleaved PARP (panel d), and actin loading control (panel e). (B) Quantitation
of the band intensities shown in (A). *p,0.05 Protein abundance of BAX and PUMA (panel a), cleaved caspase 3 and cleaved PARP (panel b) was
significantly higher and total PARP (panel b) was lower in the thyroids of ThrbPV/PVNcor1DID/DID mice.
doi:10.1371/journal.pone.0067954.g004
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activation of these two genes. The increased expression of these
genes resulted in the decreased proliferation and increased
apoptosis of tumor cells. These findings provided direct evidence
to demonstrate that, in vivo, NCOR1 can function as an oncogene
to drive thyroid cancer progression. One mechanism we
uncovered is via transcription regulation by constitute association
Figure 5. Expression of NCOR1DID alters expression of key regulators in cell proliferation and apoptosis in the thyroid of ThrbPV/
PVNcor1DID/DID mice. (A) Activated expression of the Cdkn1A and the Bax genes in the thyroid of ThrbPV/PVNcor1DID/DID mice. Quantitative real-time
RT-PCR was carried out as described in Methods and Materials. Each thyroid sample was run in triplicates with total mouse numbers of 3–5. The
differences in the expression are significant in the expression of the Cdkn1A (lanes 1 and 2) and the Bax genes (lanes 3 and 4) between ThrbPV/
PVNcor1+/+ and ThrbPV/PVNcor1DID/DID mice (lanes 5 and 6). (B) Co-immunoprecipitation of PV with p53 and NCOR1 in the thyroid of ThrbPV/PVNcor1+/+
mice (lane 1), but not with NCOR1DID in thyroid extracts of ThrbPV/PVNcor1DID/DID mice (lane 2). Lanes 3 and 4 show the p53 band (upper panel) and
NCOR1 and NCOR1DID from direct Western blot analysis from the thyroid nuclear extracts of ThrbPV/PVNcor1+/+ and ThrbPV/PVNcor1DID/DID mice,
respectively. (C and D) Recruitment of PV and NCOR1 to the p53/DNA binding sites on the promoter of the Cdkn1A gene (C) and the Bax gene (D).
ChIP assay was carried out using IgG (bars 1 and 6) or anti-p53 (bars 2 and 7) or anti-PV (bars 3 and 8) or anti-NCOR1 (bars 4 and 9) or anti-HDAC-3
(bars 5 and 10) antibodies as described in Materials and Methods. Binding was expressed as fold of changes in reference to the negative control in
which mouse IgG was used in the immunoprecipitation.*p,0.05, and ***p,0.001. NS, not significant.
doi:10.1371/journal.pone.0067954.g005
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with p53/PV to recruit the NCOR1/HDAC associated repressor
complex, which leads to aberrant chromatin acetylation around
the promoters of the p53 target genes (see Figure 6A). The
repression of p53 target genes that function as tumor suppressors is
therefore attenuated, and leads to cancer progression. Such
oncogenic roles of NCOR1 have been demonstrated in acute
promyelocyte leukemia. A fusion between the retinoic acid
receptor a (RARa) and either promyelocyte leukemic (PML) or
promyelocyte leukemic zinc finger (PLZF) genes sustain NCOR1
interaction. Consequently, RARa-mediated cell differentiation is
blocked because of a condensed chromatin structure around the
promoters of the RARa target genes [11]. However, at present we
cannot exclude the possibility that NCOR1 could act via other
pathways in addition to p53 signaling. Such possibilities await
future exploration.
The present studies also uncovered a critical role of NCOR1 in
regulating the oncogenic actions of a TR mutant, PV, via the p53
network of signaling. Previously, we showed that PV physically
interacts with the C-terminal SH domain of the p85 subunit of
phosphatidylinositol 3-kinase (PI3K), resulting in the activation of
PI3K-AKT signaling to promote thyroid carcinogenesis of ThrbPV/
PV mice [23]. Subsequently, we discovered that NCOR1, when
present in the cytoplasm, could compete with PV for binding to
the same C-terminal SH domain of the p85 subunit, thereby
attenuating the aberrant activation of PI3K-AKT signaling by PV
[39]. The present studies showed that recruitment of nuclear
NCOR1/HDAC-3 by DNA-bound p53/PV attenuated the
expression of two p53 target genes, Cdkn1A and Bax, to promote
tumor cell proliferation and to decrease apoptosis, respectively.
Therefore, NCOR1 acts in dual modes on the oncogenic actions
of PV via nuclear and extranuclear actions to affect thyroid
carcinogenesis of ThrbPV/PV mice. However, it is reasonable to
postulate that the nuclear action could be the predominant mode
of action as NCOR1 is mainly located in the nucleus. Moreover,
p53, as a central node of a complex network of signaling, when
bound to DNA and associated with PV/NCOR1/HDAC-3
repressor complex, could broadly attenuate the expression of an
array of tumor suppressors to promote carcinogenesis. This mode
of action is exemplified by the regulation of the expression of the
Cdkn1A and the Bax genes (see Figure 6). Identification of
additional p53 target genes affected by the recruitment of the
p53/PV/NCOR1/HDAC-3 repressor complex to the p53 bind-
ing sites would reveal the breadth of the p53 network extensively
affecting thyroid carcinogenesis. However, such studies are for
future investigation.
Moreover, we also cannot exclude the possibility that NCOR1-
DID could act via other pathways other than p53 signaling.
NCOR1 and the homolog NCOR2/SMRT are two intensively
studied co-repressors [40,41]. They both contain a conserved
bipartite nuclear-receptor-interaction domain (RID) and three
independent repressor domains [42]. These corepressors interact
with nuclear receptors via the motif, termed the CoRNR box [43].
However, numerous biochemical studies have suggested that RAR
preferentially recruits SMRT, whereas TR preferentially recruits
NCOR1 [44,45], mainly because of specific sequences on the
motifs as well as a TR-specific interaction domain present in
NCOR1, but not SMRT [44]. Accordingly, in the present study,
we used the mutant Ncor1DID mice in which the TR-interaction
domains were deleted, thus preventing interaction with TR or PV
[30]. We also focused our molecular analysis on the recruitment of
the PV/NCOR1/HDAC-3 repressor complex by p53 to the p53
binding sites of target genes (Figure 5). However, at present, we
cannot exclude the possibility that p53/PV could also form a PV/
SMRT/HDAC-3 repressor complex, thereby contributing to
thyroid carcinogenesis of ThrbPV/PV mice by repression of tumor
suppressors that are downstream targets of the p53-signaling.
Currently, the potential oncogenic actions of SMRT have not
been extensively investigated. Whether SMRT plays a role in
thyroid carcinogenesis would be interesting to address in future
studies.
The present results demonstrated the amelioration of the cancer
phenotypes by the expression of NCOR1DID in the thyroid of
ThrbPV/PV mice. However, the expression of NCOR1DID cannot
completely block the development of thyroid cancer. These
Figure 6. A proposed molecular model for the regulation of p53 downstream targets by PV. (A) Recruitment of the p53/PV/NCOR1/
HDAC-3 repressor complex to the p53 binding site attenuates the expression of p53 target gene in the thyroid of ThrbPV/PVNcor1+/+ mice. (B) In the
thyroid of ThrbPV/PVNcor1DID/DID mice, the DNA-bound p53/PV complex cannot recruit NCOR1DID/HDAC-3 repressor complex, thereby alleviating the
NCOR1/HDAC-3 repression effect, leading to activation of the p53-target gene.
doi:10.1371/journal.pone.0067954.g006
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findings suggest that while activation of the p53-downstream
tumor suppressors (e.g., the Cdkn1A and the Bax genes) by
NCOR1DID is crucial, other p53-independent pathways driven
by the oncogenic actions of PV are ongoing to continuously propel
thyroid cancer progression. Previously, we found that PV, via
extranuclear actions, aberrantly activates PI3K/AKT [23,24] and
integrin–Src–MAPK signaling [25] and abnormally accumulates
the oncogenic pituitary tumor transforming gene protein (PTTG)
[26,27] and ß-catenin [28]. These preclinical findings clearly show
that there are multiple oncogenic molecular pathways intercon-
nected to drive the progression. Thus, it is important to consider
using combined-drug modalities to concurrently target different
pathways for effective treatment. We have previously shown that
treatment of ThrbPV/PV mice with a PI3K inhibitor, LY294002,
effectively delays thyroid tumor progression and inhibits distant
metastasis [46]. But inhibition of the PI3K/AKT pathway alone is
not sufficient to completely block cancer development and
progression. The present studies suggest that inhibitors of histone
deacetylases could be used together in conjunction with inhibitors
of PI3K/AKT or integrin–Src–MAPK pathways. HDAC inhib-
itors have been shown to inhibit cell proliferation [47,48,49,50]
and in combination with all-trans-retinoic acid to increase re-
differentiation of human thyroid cancer cell lines [51]. Completed
Phase I and II clinical trials using various HDAC inhibitors have
shown promise for treating radioiodine-refractory metastatic
thyroid cancer [52]. Thus, treatment combining HDAC inhibitors
with newer generations of inhibitors in the PI3K/AKT and
integrin–Src–MAPK pathways could improve the efficacy offered
by a single-drug treatment.
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